Participants 59 120 6
previously untreated advanced esophagogastric cancer patients
Participants 382 506 3
patients within an open label, randomized clinical phase II trial with advanced or metastatic gastric/esophagogastric cancer
Participants 516 561 4
Previously untreated patients were randomized
Participants 928 949 6
f 118 patients enroll
Participants 1580 1625 3
 in patients with advanced esophagogastric ca
